MediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of “Hold” by Brokerages

Shares of MediWound Ltd. (NASDAQ:MDWD) have earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $31.6667.

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Wall Street Zen cut MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th.

Institutional Investors Weigh In On MediWound

A number of hedge funds have recently added to or reduced their stakes in MDWD. Sphera Funds Management LTD. increased its position in MediWound by 24.3% in the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after acquiring an additional 45,077 shares in the last quarter. Kotler Kevin acquired a new position in shares of MediWound during the fourth quarter worth approximately $6,225,000. Russell Investments Group Ltd. lifted its position in shares of MediWound by 45.1% during the fourth quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,135 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of MediWound during the fourth quarter valued at approximately $297,000. Finally, Barclays PLC increased its holdings in shares of MediWound by 32.5% in the fourth quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 3,747 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

MediWound Stock Up 3.8%

NASDAQ:MDWD opened at $16.81 on Friday. The firm has a market cap of $216.01 million, a PE ratio of -8.00 and a beta of 0.15. MediWound has a 12 month low of $14.14 and a 12 month high of $22.50. The company’s 50-day moving average price is $17.25 and its two-hundred day moving average price is $17.80.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. The firm had revenue of $1.87 million for the quarter. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%. On average, research analysts expect that MediWound will post -2.66 EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.